We use cookies

We use cookies on this website. By using our website you agree to the usage of cookies. More information on how we use cookies and how you can change your browser settings:



Cannabis & CBD

Cannabis products with a THC content of less than one percent are not subject to the narcotics legislation and are therefore being increasingly commercialized. Especially products with the non-intoxicating active substance CBD gain in importance.

THC-poor cannabis

The unauthorized use of cannabis or products derived therefrom, which have an average total THC content of at least 1.0 percent, is prohibited according to the Ordinance on Narcotics Ordinances (BetmVV-EDI, see link to the regulation in the "Laws" register). There are, however, different THC-deficient cannabis products, which are not subject to the narcotic law because they have a THC content of less than one percent. In addition to raw materials such as hemp blossoms or powders, they also include processed products such as extracts in the form of oils or pastes, bulk capsules and ready-to-use products such as dietary supplements, liquid for e-cigarettes, tobacco products, scented oils, chewing gums and ointments become.
The production and sale of THC-poor cannabis products have recently increased considerably and raise various health and legal issues. Even if these products do not fall under the Narcotic Act, they can not be distributed and promoted at will. Depending on the product category, the German Medicinal Products Act, the Food Act or the Federal Law on Product Safety are used in their industrial exploitation. Swissmedic, the Swiss Federal Office of Public Health, the Federal Office for Food Safety and Veterinary Affairs and the Federal Office for Agriculture have therefore compiled a leaflet (see document on this page) in order to sensitize the potential providers to the legal framework.
Cannabidiol (CBD)

There are over 80 cannabinoids and over 400 other active ingredients in the hemp plant. The most important cannabinoids are the intoxicating tetrahydrocannabinol (THC) and the non-intoxicating cannabidiol (CBD), which also reduces the psychotropic effect of THC. CBD is not subject to the Narcotics Act.
Among the THC-poor cannabis products, those with an increased CBD content are particularly important. Demand is growing rapidly and demand is growing. Discussions include possible therapeutic effects such as antioxidant, anti-inflammatory, anti-convulsive, antiemetic, anxiolytic or antipsychotic effects. However, the medical effect of CBD is currently under investigation (see also the> medical use of THC-containing cannabis).
It is also discussed in specialist circles whether cannabis with a lot of CBD and less than 1% THC content can be used as a substitute product in damage reduction or in the treatment of problematic cannabis use.

There are not any products in this category yet